SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

Multispecific drugs herald a new era of biopharmaceutical innovation

(2020) Raymond J. Deshaies   NATURE

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

(2019) Longchuan Bai et al.   CANCER CELL

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

(2019) Haibin Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

(2018) Jenny D. Beebe et al.   PHARMACOLOGY & THERAPEUTICS

Antisense oligonucleotides: the next frontier for treatment of neurological disorders

(2017) Carlo Rinaldi et al.   Nature Reviews Neurology

Light-switched inhibitors of protein tyrosine phosphatase PTP1B based on phosphonocarbonyl phenylalanine as photoactive phosphotyrosine mimetic

(2015) Stefan Wagner et al.   BIOORGANIC & MEDICINAL CHEMISTRY

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Benzoylphosphonate-Based Photoactive Phosphopeptide Mimetics for Modulation of Protein Tyrosine Phosphatases and Highly Specific Labeling of SH2 Domains

(2012) André Horatscheck et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Synthesis of Phosphatase-Stable, Cell-Permeable Peptidomimetic Prodrugs That Target the SH2 Domain of Stat3

(2009) Pijus K. Mandal et al.   ORGANIC LETTERS

Roles of unphosphorylated STATs in signaling

(2008) Jinbo Yang et al.   CELL RESEARCH